Curanex Pharmaceuticals Inc Common Stock (NASDAQ:CURX) — Market Cap & Net Worth
Market Cap & Net Worth: Curanex Pharmaceuticals Inc Common Stock (CURX)
Curanex Pharmaceuticals Inc Common Stock (NASDAQ:CURX) has a market capitalization of $7.99 Million ($7.99 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27579 globally and #5625 in its home market, demonstrating a 4.81% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Curanex Pharmaceuticals Inc Common Stock's stock price $0.32 by its total outstanding shares 28340812 (28.34 Million). Review Curanex Pharmaceuticals Inc Common Stock total liabilities to assess the company's total debt and financial obligations.
Curanex Pharmaceuticals Inc Common Stock Market Cap History: 2025 to 2026
Curanex Pharmaceuticals Inc Common Stock's market capitalization history from 2025 to 2026. Data shows growth from $9.37 Million to $9.07 Million (0.00% CAGR).
Curanex Pharmaceuticals Inc Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Curanex Pharmaceuticals Inc Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CURX by Market Capitalization
Companies near Curanex Pharmaceuticals Inc Common Stock in the global market cap rankings as of June 18, 2026.
Key companies related to Curanex Pharmaceuticals Inc Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Curanex Pharmaceuticals Inc Common Stock Historical Marketcap From 2025 to 2026
Between 2025 and today, Curanex Pharmaceuticals Inc Common Stock's market cap moved from $9.37 Million to $ 9.07 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $9.07 Million | -3.21% |
| 2025 | $9.37 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Curanex Pharmaceuticals Inc Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.99 Million USD |
| MoneyControl | $7.99 Million USD |
| MarketWatch | $7.99 Million USD |
| marketcap.company | $7.99 Million USD |
| Reuters | $7.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma… Read more